Owkin
Owkin Expands Into Western Europe With Nine Precision Medicine Partnerships
The firm will employ its machine learning-enabled diagnostic and drug discovery tools in nine centers across Germany, Austria, and Switzerland.
The firm has early results from more than 400 cancer samples suggesting the multimodal profiles could aid clinical decision-making and drug target discovery.
Owkin, MSD Collaborate on Digital Pathology Cancer Diagnostics
Owkin and MSD — known as Merck in the US and Canada — will develop and commercialize microsatellite instability high diagnostics in the EU for four types of cancer.
With $50M Investment in MOSAIC Project, Owkin Seeks to Become Cancer 'Drug Discovery Enterprise'
Premium
The MOSAIC research coalition brings together Owkin, NanoString, and European and US institutions to create a massive spatial omics dataset in pursuit of novel cancer biomarkers
Owkin-led Machine Learning Study IDs Possible Cancer Treatment Biomarkers Using Federated Model
Premium
AI firm Owkin used distributed on-site analysis of whole-slide images to identify triple-negative breast cancer patients who might respond to neoadjuvant therapy.